- Home
- LFST vs LIVN Comparison
LFST vs LIVN Comparison
Compare LFST & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- LIVN
- Stock Information
- Founded
- LFST 2015
- LIVN 1987
- Country
- LFST United States
- LIVN United Kingdom
- Employees
- LFST N/A
- LIVN N/A
- Industry
- LFST Medical/Nursing Services
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LFST Health Care
- LIVN Health Care
- Exchange
- LFST Nasdaq
- LIVN Nasdaq
- Market Cap
- LFST 2.3B
- LIVN 2.1B
- IPO Year
- LFST 2021
- LIVN 1993
- Fundamental
- Price
- LFST $5.94
- LIVN $43.25
- Analyst Decision
- LFST Strong Buy
- LIVN Strong Buy
- Analyst Count
- LFST 5
- LIVN 7
- Target Price
- LFST $8.50
- LIVN $59.29
- AVG Volume (30 Days)
- LFST 2.0M
- LIVN 1.0M
- Earning Date
- LFST 05-07-2025
- LIVN 05-07-2025
- Dividend Yield
- LFST N/A
- LIVN N/A
- EPS Growth
- LFST N/A
- LIVN N/A
- EPS
- LFST N/A
- LIVN N/A
- Revenue
- LFST $1,283,503,000.00
- LIVN $1,275,380,000.00
- Revenue This Year
- LFST $15.35
- LIVN $7.86
- Revenue Next Year
- LFST $13.72
- LIVN $6.07
- P/E Ratio
- LFST N/A
- LIVN N/A
- Revenue Growth
- LFST 16.31
- LIVN 7.62
- 52 Week Low
- LFST $4.64
- LIVN $32.48
- 52 Week High
- LFST $8.61
- LIVN $61.94
- Technical
- Relative Strength Index (RSI)
- LFST 46.63
- LIVN 56.31
- Support Level
- LFST $5.47
- LIVN $41.73
- Resistance Level
- LFST $6.18
- LIVN $44.13
- Average True Range (ATR)
- LFST 0.20
- LIVN 1.04
- MACD
- LFST 0.05
- LIVN -0.19
- Stochastic Oscillator
- LFST 66.20
- LIVN 37.69
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.